SCHEMBL1650867

SCHEMBL1650867

O=C(O)CCCc1nnn[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 3/20 0.41
HDAC3 O15379 1/20 0.38
MAPK1 P28482 1/20 0.38
ADRA1A P35348 1/20 0.38
HDAC4 P56524 1/20 0.38
SLC6A3 Q01959 1/20 0.38
HDAC1 Q13547 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SLC22A6 Q4U2R8 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10435516 0.94 TBXAS1 (0.47) TBXAS1LMNAALDH1A1SLC22A6MAPT
SCHEMBL1898999 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL20659611 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL1892347 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL1888744 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL1889345 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL8464719 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL420407 0.93 TBXAS1 (0.50) TBXAS1LMNAALDH1A1MAPTTSHR
SCHEMBL2704416 0.88 CHRM1 (0.39) TBXAS1LMNAALDH1A1GAA
SCHEMBL4570513 0.83 PAOX (0.32) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112218858-B 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy 托马斯·黑勒戴药物研究基金会 2024-06-18 CN claimed
CN-101993421-B Synthesis and application of blue-fluorescence luminous zinc metal complex FUJIAN MATTER STRUCTURE 2014-04-16 CN claimed
CN-120153318-A Photosensitive resin composition, method for producing cured relief pattern using same, and method for producing polyimide film 旭化成株式会社 2025-06-13 CN disclosed
CN-112218858-B 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy 托马斯·黑勒戴药物研究基金会 2024-06-18 CN disclosed
EP-4281119-A1 PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER SCV - SpezialChemikalienVertrieb GmbH (DE) 2023-11-29 EP disclosed
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
WO-2022157277-A1 PRECURSOR MARKER AND RADIOTRACER FOR NUCLEAR-MEDICAL DIAGNOSIS AND THERAPY OF BONE-METASTATIC PROSTATE CANCER SCV - SpezialChemikalienVertrieb GmbH (DE) 2022-07-28 WO disclosed
CN-110078735-B Pyrrolopyrimidine compounds having antitumor activity and use thereof 河北医科大学 2022-02-18 CN disclosed
EP-3777898-A2 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Endocyte, Inc. (US) 2021-02-17 EP disclosed
EP-3533473-A2 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Endocyte, Inc. (US) 2019-09-04 EP disclosed
US-20160287731-A1 Compounds for Positron Emission Tomography ENDOCYTE, INC 2016-10-06 US disclosed
WO-2015073678-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY ENDOCYTE, INC. (US) 2015-05-21 WO disclosed
CN-101993421-B Synthesis and application of blue-fluorescence luminous zinc metal complex FUJIAN MATTER STRUCTURE 2014-04-16 CN disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
CN-101993421-A Synthesis and application of blue-fluorescence luminous zinc metal complex FUJIAN INST RES STR MATTER CAS 2011-03-30 CN disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
US-4925948-A CEPHALOSPORIN ANTIBIOTIC CHEMICAL INTERMEDIATES FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-15 US disclosed
EP-0055465-B1 7-ACYLAMINOCEPHALOSPORANIC ACID DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-08-23 EP disclosed
US-4596829-A Pharmaceuticals FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-06-24 US disclosed
US-4438113-A 7-Acylaminocephalosporanic acid derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160287731-A1 Compounds for Positron Emission Tomography FOLH1, FOLR2, FOLR1 TBXAS1 3537/4885HDAC3 3954/4885MAPK1 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.